var data={"title":"Measles, mumps, and rubella vaccines (combined): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Measles, mumps, and rubella vaccines (combined): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6509?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=measles-mumps-and-rubella-vaccines-combined-drug-information\" class=\"drug drug_general\">see &quot;Measles, mumps, and rubella vaccines (combined): Drug information&quot;</a> and <a href=\"topic.htm?path=measles-mumps-and-rubella-vaccines-combined-patient-drug-information\" class=\"drug drug_patient\">see &quot;Measles, mumps, and rubella vaccines (combined): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191454\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>M-M-R II</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191455\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>M-M-R II;</li>\n      <li>Priorix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060004\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Live (Viral)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059996\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=measles-mumps-and-rubella-vaccines-combined-drug-information\" class=\"drug drug_general\">see &quot;Measles, mumps, and rubella vaccines (combined): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The minimum interval between two doses of MMR vaccine is 28 days (CDC/ACIP [McLean 2013]). Refer to Additional Information for a description of acceptable evidence of immunity. Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered &le;4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary immunization: </b>Children &ge;12 months: SubQ: 0.5 mL per dose for a total of 2 doses given as follows: 12 to 15 months of age and the second dose at 4 to 6 years of age; the second dose is recommended prior to entering kindergarten or first grade. The second dose may be administered at any time provided at least 28 days have elapsed since the first dose (CDC/ACIP [McLean 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catch-up immunization</b> (CDC/ACIP [McLean 2013]): School-aged Children and Adolescents: Ensure that 2 doses have been given at least 28 days apart</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Measles outbreak without acceptable evidence of immunity and at risk for exposure: Note:</b> Should be administered within 72 hours postexposure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 to 11 months: SubQ: 0.5 mL per dose as a single dose (CDC/ACIP [McLean 2013]). Children should be vaccinated at &ge;12 months with standard 2-dose series</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 4 years: Children who received 1 dose (0.5 mL SubQ) of MMR should be considered for a second dose if the outbreak involves preschool-aged children (CDC/ACIP [McLean 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Mumps outbreak (eg, community):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 1 to 4 years (without acceptable evidence of immunity and at risk for exposure): Children who received 1 dose of MMR should be considered for a second dose (0.5 mL SubQ) if the outbreak involves preschool-aged children (CDC/ACIP [McLean 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (fully immunized [2 previous MMR doses]); community outbreak: A third dose of MMR vaccine may be considered; appropriate patients should be guided by public health officials (ACIP/CDC [Marin 2018]); in a large, cohort trial (total: n=20,496; treatment cohort: n= 4,783; age range: 18 to 24 years), subjects who received a third dose of MMR vaccine had significantly decreased incidence of mumps compared to those students who had only received 2 doses (Cardemil 2017); consult local public health authorities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b> Household/close contacts of immunocompromised persons without acceptable evidence of immunity:</b> Children &ge;12 months and Adolescents: SubQ: 0.5 mL per dose for a total of 2 doses administered at least 28 days apart unless they have acceptable evidence of immunity (CDC/ACIP [McLean 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV infection without evidence of MMR immunity:</b> Children &ge;12 months and Adolescents: SubQ: 0.5 mL per dose. Children and adolescents with HIV infection and without evidence of severe immunosuppression should have 2 additional doses of MMR; those with perinatal HIV infection who were vaccinated prior to effective ART should have 2 additional doses of MMR once ART is established (CDC/ACIP [McLean 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>International travel, without evidence of immunity</b> (CDC/ACIP [McLean 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 to 11 months: SubQ: 0.5 mL per dose. Administer 1 dose of MMR before departure from the United States; these infants should be revaccinated with 2 doses of MMR with the first dose between 12 to 15 months of age (and at least 28 days after the previous dose; target 12 months of age if child remains in area where disease risk if high) and the second dose at least 28 days later.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 months and Adolescents: SubQ: 0.5 mL per dose. Administer 2 doses of MMR before departure from the United States with the second dose at least 28 days later.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Primary immunization:</b> SubQ: 0.5 mL per dose for a total of 1 or 2 doses administered at least 28 days apart based upon the following criteria (CDC/ACIP [McLean 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Adults born prior to 1957:</i> Considered immune to measles, mumps, and rubella but may be vaccinated with 1 dose if they do not have contraindications to the vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i> Adults born in or after 1957:</i> Should be vaccinated unless they have acceptable evidence of immunity</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults who received inactivated or unknown type of measles vaccine during 1963 to 1967: One or two doses of MMR</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults who received inactivated or unknown type of mumps vaccine before 1979 and who are at high risk: Two doses of MMR</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Health care personnel:</i> Persons born during or after 1957 should have 2 doses of vaccine unless they have acceptable evidence of immunity. Unvaccinated persons born prior to 1957 should also consider vaccination with 2 doses of MMR for measles and mumps or 1 dose of MMR for rubella unless they have laboratory evidence or laboratory confirmation of disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>HIV infection (without severe immunosuppression):</i> 2 doses of MMR unless there is acceptable evidence of immunity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Household/close contacts of immunocompromised persons:</i> 2 doses of MMR unless there is acceptable evidence of immunity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>International travelers:</i> 2 doses of MMR prior to travel unless there is acceptable evidence of immunity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Measles, mumps, or rubella outbreak (community):</i> Adults who received one dose of MMR should be considered for a second dose if the outbreak involves measles or mumps in adults. Vaccination should also be considered for persons born prior to 1957 without evidence of immunity who may be exposed to mumps. A single dose of a rubella-containing vaccine is considered adequate vaccination during a rubella outbreak. During a mumps outbreak in a college setting, a third dose of MMR vaccine significantly decreased the incidence of mumps compared to those students who had only received 2 doses (Cardemil 2017); consult local public health authorities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Measles, mumps, or rubella outbreak (health care facility):</i> Unvaccinated health care personnel without evidence of immunity regardless of birth year should receive 2 doses during a measles or mumps outbreak and one dose during a rubella outbreak</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Students:</i> Persons entering post high school educational facilities should receive 2 doses of MMR unless they have acceptable evidence of immunity prior to enrollment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Women of childbearing potential:</i> 1 dose of MMR unless they have acceptable evidence of immunity. Vaccination should not be given during pregnancy and pregnancy should be avoided for 28 days after vaccine administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191436\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">M-M-R II: Measles virus &ge;1000 TCID<sub>50</sub>, mumps virus &ge;20,000 TCID<sub>50</sub>, and rubella virus &ge;1000 TCID<sub>50</sub> [contains albumin (human), bovine serum, chicken egg protein, gelatin, neomycin, sorbitol, and sucrose 1.9 mg/vial; supplied with diluent]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191422\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734125\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmr.html&amp;token=03S8ugZauTiHyhvv3nRjemTZhqTyJ/g1ZFFhVKOx8KN0aGvh82vX9gUZj3JVzLLiUjBQIaG1iqNFdxEaIckrWQ==&amp;TOPIC_ID=12943\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmr.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060008\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer as soon as possible following reconstitution; administer subcutaneously into the anterolateral aspect of the thigh or arm; not for IV administration. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191449\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">To maintain potency, the lyophilized vaccine must be stored between -50&deg;C to 8&#730;C (-58&deg;F to 46&#730;F). Temperatures below -50&deg;C (-58&deg;F) may occur if stored in dry ice. Prior to reconstitution, store the powder at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Diluent may be stored in refrigerator or at room temperature. Do not freeze diluent. Use as soon as possible following reconstitution; may be stored under refrigeration for up to 8 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060007\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Provide active immunity to measles, mumps, and rubella viruses (FDA approved in ages &ge;12 months and adults)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following (CDC/ACIP [McLean 2013]):</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; All children (first dose given at 12 to 15 months of age)</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Adults born 1957 or later (without evidence of immunity or documentation of vaccination). Vaccine may be given to adults born prior to 1957 if they do not have contraindications to the MMR vaccine.</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">&bull; Adults at higher risk for exposure to and transmission of measles, mumps, and rubella should receive special consideration for vaccination, unless an acceptable evidence of immunity exists. This includes international travelers, persons attending colleges and other post high school education, and persons working in healthcare facilities.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6266587\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MMR (measles, mumps and rubella virus vaccine) may be confused with MMRV (measles, mumps, rubella, and varicella) vaccine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">MMR (measles, mumps and rubella virus vaccine) may be confused with MCV (meningococcal conjugate vaccine; MCV4 is the correct abbreviation)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191471\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Syncope, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Acute disseminated encephalomyelitis, ataxia, dizziness, Guillain-Barr&eacute; syndrome, headache, irritability, malaise, nerve deafness, paresthesia, polyneuropathy, retrobulbar neuritis, seizure, subacute sclerosing panencephalitis, transverse myelitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme, IgA vasculitis (Henoch-Schnolein purpura/acute hemorrhagic edema of infancy), morbilliform rash, pruritus, rash, Stevens-Johnson syndrome, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Diabetes mellitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, nausea, pancreatitis, parotitis, sore throat, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Epididymitis, orchitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukocytosis, lymphadenopathy (regional), purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Atypical measles</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (including burning, induration, redness, stinging, swelling, tenderness, vesiculation, wheal and flare)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthropathy (arthralgia/arthritis: Women 12% to 26%; children &le;3%), myalgia, panniculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis, oculomotor nerve paralysis, optic neuritis, optic papillitis, retinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, cough, pneumonia, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Febrile seizures, fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Aseptic meningitis (associated with Urabe strain of mumps vaccine), brain disease, encephalitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191441\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to measles, mumps, and/or rubella vaccine or any component of the formulation (including neomycin); current febrile respiratory illness or other febrile infection; patients receiving immunosuppressive therapy (does not include corticosteroids as replacement therapy); primary and acquired immunodeficiency states; individuals with blood dyscrasias, leukemia, lymphomas, or other malignant neoplasms affecting the bone marrow or lymphatic systems; family history of congenital or hereditary immunodeficiency (until immune competence in the vaccine recipient is demonstrated); pregnancy </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191426\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever). Although fever is a contraindication per the manufacturer, current guidelines allow for administration to patients with mild acute illness (without fever) (ACIP [Kroger 2017]; CDC/ACIP [McLean 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS disorders: Use with caution in patients with history of cerebral injury, seizures, or other conditions where stress due to fever should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Measles exposure: Exposure to measles is not a contraindication to vaccine; use within 72 hours of exposure may provide some protection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mumps exposure: Postexposure vaccination has not been shown to prevent or alter disease following mumps exposure (CDC/ACIP [McLean 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rubella exposure: Postexposure vaccination has not been shown to prevent or alter disease following rubella exposure (CDC/ACIP [McLean 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Use with caution in patients with thrombocytopenia and those who develop thrombocytopenia after first dose; thrombocytopenia may worsen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: Defer vaccination in patients with active untreated tuberculosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune globulins: Recent administration of immune globulins may interfere with immune response. Guidelines with suggested administration intervals are available (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Use is contraindicated in severely immunocompromised patients. The ACIP does not recommend vaccination for persons with primary or acquired immunodeficiency (including immunosuppression associated with cellular immunodeficiency, hypogammaglobulinemia, dysgammaglobulinemia and AIDs, or severe immunosuppression associated with HIV); persons with blood dyscrasia, leukemia, lymphoma, or other malignant neoplasms which affect the bone marrow or lymphatic system; persons with a family history of congenital or hereditary immunodeficiency in first degree relatives (unless immunocompetence can be established); persons taking systemic corticosteroid therapy for &ge;2 weeks in doses of corticosteroids &ge;2 mg/kg of body weight or prednisone (or equivalent) &ge;20 mg/day for persons who weigh &gt;10 kg. Patients with HIV infection, who are asymptomatic and not severely immunosuppressed may be vaccinated (severe immunosuppression is defined as CD4+ T-lymphocyte &lt;15% at any age or CD4 count &lt;200 lymphocytes/mm<sup>3</sup> for persons &gt;5 years) (CDC/ACIP [McLean 2013]). Patients with leukemia who are in remission and who have not received chemotherapy for at least 3 months may be vaccinated. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Health care workers: Acceptable evidence of immunity is recommended for health care workers (CDC/ACIP [McLean 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Safety and efficacy of measles vaccine has not been established in children &lt;6 months of age and safety and efficacy of mumps and rubella vaccines have not been established in &lt;12 months of age. Local health departments may recommend vaccine to children 6 to 12 months of age in outbreak situations, but this would not count towards their immunization series.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Students: Acceptable evidence of immunity is recommended for students entering post high school educational institutions (CDC/ACIP [McLean 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Travelers to endemic areas: Acceptable evidence of immunity is recommended for travelers to endemic areas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Some dosage forms may contain human albumin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Egg allergy: Vaccine may contain trace amounts of chick embryo antigen. Use caution in patients with history of immediate hypersensitivity/anaphylactic reactions following egg ingestion. Generally, the MMR vaccine can be safely administered to persons with an egg allergy (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gelatin: Products may contain gelatin. Use is contraindicated in patients with a history of anaphylactic/anaphylactoid reaction to gelatin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neomycin sensitivity: Manufactured with neomycin. Use is contraindicated in patients with history of anaphylactic/anaphylactoid reactions to neomycin. Contact dermatitis due to neomycin is not a contraindication to the vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2017]; ACIP [Robinson 2017]). Specific recommendations for vaccination in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood products: Recent administration of blood or blood products may interfere with immune response. Guidelines with suggested administration intervals are available (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299648\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191430\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12943&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Axicabtagene Ciloleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for at least 6 weeks prior to initiation of lymphodepleting therapy, during axicabtagene ciloleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose azathioprine (3 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of azathioprine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclizumab: May enhance the adverse/toxic effect of Vaccines (Live). Daclizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Canadian labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment.  U.S. labeling does not mention this.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinal infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<b> Exceptions: </b>AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone (Systemic); Budesonide (Systemic); Corticotropin; Cortisone; Cytarabine (Liposomal); Deflazacort; Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live). Leflunomide may diminish the therapeutic effect of Vaccines (Live). Management: The ACIP guidelines state that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy. However, the ACR does not recommend avoiding live vaccines in patients being treated with leflunomide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live). Mercaptopurine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose 6-mercaptopurine (1.5 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of mercaptopurine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the adverse/toxic effect of Vaccines (Live). Ocrelizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rabies Immune Globulin (Human): May diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rho(D) Immune Globulin: May diminish the therapeutic effect of Measles, Mumps, and Rubella Virus Vaccine. Management: Do not delay administration of the measles, mumps, and rubella virus vaccine in women who have recently received Rho (D) immune globulin.  If possible, women should be tested 3 or more months after vaccine administration to ensure immunity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Tisagenlecleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for two weeks prior to initiation of lymphodepleting therapy, during tisagenlecleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later.<b> Exceptions: </b>Adenovirus (Types 4, 7) Vaccine; Cholera Vaccine; Rotavirus Vaccine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live, attenuated vaccines before, during, or after (prior to B-cell recovery) venetoclax treatment.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191433\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191445\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Animal reproduction studies have not been conducted. It is not known whether this vaccine can cause fetal harm or affect reproduction capacity. Based on information collected following inadvertent administration during pregnancy, adverse events have not been observed following use of rubella vaccine. However, theoretical risks cannot be ruled out; use of this vaccine is contraindicated in pregnant females and should not be administered to women trying to conceive. The manufacturer recommends that pregnancy be avoided for 3 months after vaccine administration. The Advisory Committee on Immunization Practices (ACIP) recommends that pregnancy should be avoided for 28 days following vaccination. The risk of congenital rubella syndrome following vaccination is significantly less than the risk associated following infection; therefore, inadvertent administration of MMR during pregnancy is not considered an indication to terminate pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse consequences of natural infection in unvaccinated pregnant women have been reported. Measles infection during pregnancy may increase the risk of premature labor, preterm delivery, spontaneous abortion and low birth weights. Rubella infection during the first trimester may lead to miscarriages, stillbirths, and congenital rubella syndrome (includes auditory, ophthalmic, cardiac and neurologic defects; intrauterine and postnatal growth retardation); fetal rubella infection can occur during any trimester of pregnancy. Maternal mumps infection during the first trimester may increase the risk of spontaneous abortion or intrauterine fetal death. Sterility in males and infertility in prepubescent females may also occur with natural mumps infection.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Prenatal screening is recommended for all pregnant women who lack evidence of rubella immunity. Women of childbearing age without documentation of rubella vaccination or serologic evidence of immunity should be vaccinated (for women of childbearing potential, birth prior to 1957 is not acceptable evidence of immunity to rubella). Women who are pregnant should be vaccinated upon completion or termination of pregnancy, prior to discharge. Household contacts of pregnant women may be vaccinated (CDC/ACIP [McLean, 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13929200\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191425\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As a live, attenuated vaccine, MMR vaccine offers active immunity to disease caused by the measles, mumps, and rubella viruses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21182413\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: The median seroconversion after 1 vaccine dose is 96% (measles), 99% (rubella), mumps (94%) (CDC/ACIP [McLean 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: The median duration of immunity after 2 doses is &ge;15 years for all components of the vaccine (CDC/ACIP [McLean 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060011\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Using separate sites and syringes, MMR may be administered concurrently with DTaP or <i>Haemophilus</i> b conjugate vaccine (PedvaxHIB&reg;). Varicella vaccine may be administered with MMR using separate sites and syringes; however, if not administered simultaneously, doses should be separated by at least 30 days. Unless otherwise specified, MMR should be given 1 month before or 1 month after live viral vaccines.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Acceptable presumptive evidence of immunity includes one of the following (CDC/ACIP [McLean 2013]): </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">1. Documentation of adequate vaccination (for measles, mumps, and rubella). Adequate vaccination for mumps and measles is defined as 1 dose of a live virus vaccine for preschool children and adults not at high risk and 2 doses of a live virus vaccine for school-aged children and high-risk adults. Healthcare personnel (paid and unpaid workers with potential exposure), international travelers, and students in institutions of post high school education are considered high-risk adults. </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">2. Laboratory evidence of immunity or laboratory confirmation of disease (for measles, mumps, and rubella) </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">3. Birth prior to 1957 (measles, mumps, and rubella); for women of childbearing potential, birth prior to 1957 is not acceptable evidence of immunity to rubella.</p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:2em;\">4. Documentation of physician-diagnosed disease (for measles, mumps, or rubella) is not acceptable evidence of immunity.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Previous vaccination: </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Measles: Persons who received a measles vaccine of unknown type, an inactivated measles vaccine, or further attenuated measles vaccine accompanied by immune globulin or high-titer immune globulin should be considered unvaccinated (CDC/ACIP [McLean 2013]). </p>\n    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">Mumps: Persons vaccinated prior to 1979 with either killed mumps vaccine or a mumps vaccine of unknown type and who are at high risk for infection should be considered for revaccination with 2 doses of MMR vaccine (CDC/ACIP [McLean 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F191447\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>M-M-R II (AU, CZ, ID, MY, NZ, TH);</li>\n      <li>M-M-R Vax (AT, DE);</li>\n      <li>M-M-R Vaxpro (IE, IS, LT, SI, SK);</li>\n      <li>M.M.R. Vaccine (KR);</li>\n      <li>MMR (EG);</li>\n      <li>MMR II (AE, AR, BH, CH, CN, GB, HK, NO, PH, QA, SA, SE, TW, VN);</li>\n      <li>Morupar (MX, PH);</li>\n      <li>Mumeru Vax (PH);</li>\n      <li>Pluserix (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Priorix (AE, AU, BB, BM, BS, BZ, CY, ES, GB, GY, IE, IL, JM, KR, KW, LB, LK, NL, NO, PH, RO, SA, SE, SR, TT, TW);</li>\n      <li>Prioryks (UA);</li>\n      <li>R.O.R. Vax (FR);</li>\n      <li>Trimovax (AE, BG, HK, IT, PK, TW);</li>\n      <li>Triviraten Berna (HK, MY, NZ, PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cardemil CV, Dahl RM, James L, et al. Effectiveness of a third dose of MMR vaccine for mumps outbreak control. <i>N Engl J Med</i>. 2017;377(10):947-956.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-vaccines-combined-pediatric-drug-information/abstract-text/28877026/pubmed\" target=\"_blank\" id=\"28877026\">28877026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-vaccines-combined-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marin M, Marlow M, Moore KL, Patel M. Recommendation of the advisory committee on immunization practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. <i>MMWR Morb Mortal Wkly Rep</i>. 2018;67(1):33-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-vaccines-combined-pediatric-drug-information/abstract-text/29324728/pubmed\" target=\"_blank\" id=\"29324728\">29324728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2013;62(RR-04):1-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-vaccines-combined-pediatric-drug-information/abstract-text/23760231/pubmed\" target=\"_blank\" id=\"23760231\">23760231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M-M-R II (measles, mumps, and rubella virus vaccine live) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &quot;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&quot; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-vaccines-combined-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-vaccines-combined-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-and-rubella-vaccines-combined-pediatric-drug-information/abstract-text/24311479 /pubmed\" target=\"_blank\" id=\"24311479 \">24311479 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12943 Version 123.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F191454\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F191455\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060004\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059996\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F191436\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F191422\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734125\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060008\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F191449\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060007\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6266587\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F191471\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F191441\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F191426\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299648\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F191430\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F191433\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F191445\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13929200\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F191425\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F21182413\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1060011\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F191447\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12943|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=measles-mumps-and-rubella-vaccines-combined-drug-information\" class=\"drug drug_general\">Measles, mumps, and rubella vaccines (combined): Drug information</a></li><li><a href=\"topic.htm?path=measles-mumps-and-rubella-vaccines-combined-patient-drug-information\" class=\"drug drug_patient\">Measles, mumps, and rubella vaccines (combined): Patient drug information</a></li></ul></div></div>","javascript":null}